Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
- Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and others
- Led by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera’s proprietary three-pillar discovery platform is designed to enable prolonged radioligand tumor retention
- Proceeds will support clinical development of Actithera’s fibroblast activation protein (FAP)-targeting candidate and pipeline expansion
Oslo, Norway and Cambridge, Massachusetts — 9 July 2025 — Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the close of an oversubscribed $75.5 million Series A financing round. The financing will support the advancement of Actithera’s lead FAP asset into clinical development in multiple indications, while also enabling the continued development of its proprietary RLT discovery platform and preclinical pipeline.
